Graves’ ophthalmopathy (GO) is an autoimmune disease, and there is no specific treatment drug. Glucocorticoid (GC) therapy is still the first-line therapy for patients with moderate to severe GO. Targeted therapy may become a novel treatment due to GC’s adverse drug reactions. As the in-depth study of the pathogenesis of GO, many targeted drugs with randomized clinical trial (RCT) treatment have appeared in recent years, such as anti-insulin growth factor 1 receptor (teprotumumab), anti-CD20 (rituximab) and anti-interleukin(IL)-6 receptor (tocilizumab). It is worth noting that teprotumumab has been approved by US Food and Drug Administration in recently, and may quickly become the first-line therapy for GO. The anti-B cell stimulating factor (belimumab) which is undergoing RCT is waiting for the result of RCT to reveal. Anti-tumor necrosis factor-α (such as etanercept, adalimumab, and infliximab) which only used in case reports requires RCT further verification. In addition, anti-IL-17/IL-23, thyroid stimulating hormone receptor, CD40 targets and target therapies may have potential clinical value for GO due to the successful use of these target therapies in vitro experiments and other autoimmune diseases. This paper focus on the progress of targeted therapy of GO in China and abroad in recent years.
Objective To investigate the inhibitory effect of survivin antisense oligonucleotides (ASODN) on proliferation of pancreatic cancer cells PANC-1. Methods The ASODN and sense oligodeoxynucleotides (SODN) were complementary to survivin sequences. FAM-marked ASODN was transfected into PANC-1 cells mediated by positive ion liposome as ASODN group. Blank control group (normal cells), negative control group (normal medium)， and SODN group were established for comparison. The transfection efficiency was detected by flow cytometry (FCM) after transfection; MTT assay was used to detect cytotoxicity; Cell morphological changes were examined by transmission electron microscopy; The cell cycle and apoptotic rate were analyzed by FCM; Immunohistochemical staining techniques were used, and the expressions of survivin were observed under light microscopy, examined and analysed by computer image. Results ①The transfection efficiency was 31.9%, 37.4%, 41.4%, 52.6%, 24.2%, 11.4%, 16.1%, and 15.5% when the transfecting concentration of ASODN was 50, 100, 150, 200, 250, 400, 600, and 800 nmol/L, respectively; The transfection efficiency was 12.0%, 50.8%, and 11.2% when the inoculated cells was 2×104/well, 2×105/well, and 2×106/well, respectively; The transfection efficiency was 58.8%, 34.0%, and 23.6% when 2 μl, 3 μl, and 4 μl liposome was used during transfection, respectively. ②Cell gap was oversize, morphous was round, adherent cells were less after transfection under fluorescence microscope. ③The inhibition rate in the ASODN group was higher than that in each control group (Plt;0.05) on 24, 36, 48 h after treating by survivin ASODN, which increased as time prolonged (Plt;0.05). ④The apoptosis showed a ladder-shaped line in the ASODN group. ⑤Apoptotic morphology was demonstrated in the ASODN group, such as apoptotic cells with nuclear chromatin highly concentrated, crescent nuclear staining aggregated by the side nuclear membrane, nucleolus disappeared by AO and EB stains. ⑥The apoptotic rate 〔（38.1±3.4）%〕 in the ASODN group was higher than that in the SODN group 〔（4.16±1.7）%〕, Plt;0.05. ⑦G2/M cell cycle arrested in the ASODN group. ⑧After transfection, the expression of survivin protein in the ASODN group was significantly lower than that of each control group (Plt;0.05). Conclusions The optimal transfection conditions are as following: the cell count of 2×105/well, concentration of ASODN 200 nmol/L, and cationic liposome oligofectamine 2 μl, respectively. Survivin ASODN can inhibit the proliferation of pancreatic cancer cells and induce their apoptosis.